tiprankstipranks
Advertisement
Advertisement

CCCC Stock Latest News

C4 Therapeutics presents further analysis from cemsidomide trial
The FlyC4 Therapeutics presents further analysis from cemsidomide trial
9d ago
CCCC
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
PremiumCompany Announcements
C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress
9d ago
8K
CCCC
C4 Therapeutics jumps after Bristol Myers myeloma data
PremiumThe Fly
C4 Therapeutics jumps after Bristol Myers myeloma data
22d ago
BMY
CCCC
C4 Therapeutics Realigns Finance Leadership After Officer Departure
PremiumCompany Announcements
C4 Therapeutics Realigns Finance Leadership After Officer Departure
1M ago
8K
CCCC
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
PremiumThe Fly
C4 Therapeutics reports Q1 EPS (20c), consensus (26c)
1M ago
CCCC
C4 Therapeutics Reports Q1 Results and Clinical Advancements
PremiumCompany AnnouncementsC4 Therapeutics Reports Q1 Results and Clinical Advancements
1M ago
8K
CCCC
Is CCCC a Buy, Before Earnings?
Premium
Pre-Earnings
Is CCCC a Buy, Before Earnings?
1M ago
CCCC
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
Premium
Company Announcements
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
2M ago
8K
CCCC
C4 Therapeutics expands long-term partnership with Roche
PremiumThe Fly
C4 Therapeutics expands long-term partnership with Roche
2M ago
CCCC
CHRO
C4 Therapeutics doses first patient in cemsidomide trial
PremiumThe Fly
C4 Therapeutics doses first patient in cemsidomide trial
3M ago
CCCC
C4 Therapeutics price target raised to $7 from $5 at Barclays
PremiumThe Fly
C4 Therapeutics price target raised to $7 from $5 at Barclays
4M ago
CCCC
C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
PremiumRatings
C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating
4M ago
CCCC
C4 Therapeutics reports Q4 EPS (18c), consensus (34c)
PremiumThe FlyC4 Therapeutics reports Q4 EPS (18c), consensus (34c)
4M ago
CCCC
C4 Therapeutics price target raised to $30 from $20 at Brookline
Premium
The Fly
C4 Therapeutics price target raised to $30 from $20 at Brookline
4M ago
CCCC
C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
Premium
The Fly
C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial
4M ago
CCCC
CCCC Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CCCC Upcoming Earnings Report: What to Expect?
4M ago
CCCC
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors
PremiumCompany Announcements
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors
5M ago
CCCC
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
PremiumCompany Announcements
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
5M ago
8K
CCCC
C4 Therapeutics outlines milestones through 2028
PremiumThe Fly
C4 Therapeutics outlines milestones through 2028
5M ago
CCCC
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch
PremiumCompany AnnouncementsC4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch
5M ago
CCCC
C4 Therapeutics price target lowered to $5 from $10 at Barclays
Premium
The Fly
C4 Therapeutics price target lowered to $5 from $10 at Barclays
6M ago
CCCC
C4 Therapeutics’ Innovative Drug Development and Promising Clinical Trials Support Buy Rating
Premium
Ratings
C4 Therapeutics’ Innovative Drug Development and Promising Clinical Trials Support Buy Rating
7M ago
CCCC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >